SYM001 / Symmune Therap - LARVOL DELTA

Development and clinical application of recombinant polyclonal antibodies. (PubMed, Front Immunol) - "This review critically analyzes the four RPABs candidates that have entered clinical trials to date (Sym001, Sym004, Sym013, and Sym015), all developed by Symphogen using its proprietary Sympress™ platform. We conclude that without independent validation of manufacturing consistency, pharmacokinetic-based component ratio design, and a dedicated regulatory pathway, RPABs face an uncertain future. Recommendations for future development are provided."

Journal • Review • Immunology • Oncology